Robert Francomano - 06 Dec 2023 Form 4 Insider Report for SELLAS Life Sciences Group, Inc. (SLS)

Reporting relationship: Chief Commercial Officer
Issuer ticker: SLS
Reported as of: 06 Dec 2023
Net transaction value: -$1,169
SEC form: 4
Accepted by SEC: 08 Dec 2023, 16:10:31 UTC
Prior SEC filing: 03 Feb 2023
Next SEC filing: 25 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ Robert Francomano

Key filing fact

Robert Francomano filed Form 4 for SELLAS Life Sciences Group, Inc. (SLS) on 08 Dec 2023.

Key facts

This page summarizes Robert Francomano's Form 4 filing for SELLAS Life Sciences Group, Inc. (SLS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 08 Dec 2023, 16:10.

Change

Previous filing in this sequence was filed on 03 Feb 2023.
Current net transaction value: -$1,169.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SLS transaction

Class A Common Stock

Other

Transaction value: $1,169
Shares: -1,082
Change %: -4.9%
Price: $1.08
Shares after: 20,918
Date: 06 Dec 2023
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Transaction relates to shares of common stock withheld by SELLAS Life Sciences Group, Inc. (the "Issuer") to cover tax withholding obligations of the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs").

Footnote F2

Represents the number shares of common stock withheld by the Issuer to cover tax withholding obligations of the Reporting Person in connection with the vesting of RSUs.